{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:15:39Z","timestamp":1790806539414,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020083","name":"Forschungsrat des Kantonsspitals Aarau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate antibiotic prophylaxis in transrectal prostate biopsies due to the recommendation of the European Medicines Agency (EMA): We describe our single center experience switching from ciprofloxacin to fosfomycin trometamol (FMT) alone and to an augmented prophylaxis combining fosfomycin and trimethoprim\/sulfamethoxazole (TMP\/SMX).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between 01\/2019 and 12\/2020 we compared three different regimes. The primary endpoint was the clinical diagnosis of an infection within 4\u00a0weeks after biopsy. We enrolled 822 men, 398 (48%) of whom received ciprofloxacin (group-C), 136 (16.5%) received FMT (group-F) and 288 (35%) received the combination of TMP\/SMX and FMT (group-BF).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Baseline characteristics were similar between groups. In total 37\/398 (5%) postinterventional infections were detected, of which 13\/398 (3%) vs 18\/136 (13.2%) vs 6\/288 (2.1%) were detected in group-C, group-F and group-BF respectively. The relative risk of infectious complication was 1.3 (CI 0.7\u20132.6) for group-C vs. group-BF and 2.8 (CI 1.4\u20135.7) for group-F vs. group-BF respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The replacement of ciprofloxacin by fosfomycin alone resulted in a significant increase of postinterventional infections, while the combination of FMT and TMP\/SMX had a comparable infection rate to FQ without apparent adverse events. Therefore, this combined regimen of FMT and TMP\/SMX is recommended.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-05048-4","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T18:23:31Z","timestamp":1716920611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of ciprofloxacin versus fosfomycin versus fosfomycin plus trimethoprim\/sulfamethoxazole for preventing infections after transrectal prostate biopsy"],"prefix":"10.1007","volume":"42","author":[{"given":"Alberto","family":"Bovo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Manka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wetterauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph Andreas","family":"Fux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Wyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Prause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"issue":"3","key":"5048_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00345-017-2163-9","volume":"36","author":"MJ Roberts","year":"2018","unstructured":"Roberts MJ, Scott S, Harris PN, Naber K, Wagenlehner FME, Suhail AR (2018) Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World J Urol 36(3):323\u2013330","journal-title":"World J Urol"},{"key":"5048_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.urology.2016.12.011","volume":"104","author":"MJ Roberts","year":"2017","unstructured":"Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K et al (2017) Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches. Urology 104:11\u201321","journal-title":"Urology"},{"issue":"3","key":"5048_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.eururo.2016.08.004","volume":"71","author":"M Borghesi","year":"2017","unstructured":"Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S et al (2017) Complications after systematic, random, and image-guided prostate biopsy. Eur Urol 71(3):353\u2013365","journal-title":"Eur Urol"},{"issue":"2","key":"5048_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00345-021-03862-8","volume":"40","author":"CJ Parkin","year":"2022","unstructured":"Parkin CJ, Gilbourd D, Grills R, Chapman S, Weinstein S, Joshi N et al (2022) Transrectal ultrasound-guided prostate needle biopsy remains a safe method in confirming a prostate cancer diagnosis: a multicentre Australian analysis of infection rates. World J Urol 40(2):453\u2013458","journal-title":"World J Urol"},{"issue":"1","key":"5048_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bju.15062","volume":"126","author":"AS Tamhankar","year":"2020","unstructured":"Tamhankar AS, El-Taji O, Vasdev N, Foley C, Popert R, Adshead J (2020) The clinical and financial implications of a decade of prostate biopsies in the NHS: analysis of Hospital Episode Statistics data 2008\u20132019. BJU Int 126(1):133\u2013141","journal-title":"BJU Int"},{"issue":"6","key":"5048_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000074526","volume":"49","author":"K Charalabopoulos","year":"2003","unstructured":"Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N (2003) Penetration of antimicrobial agents into the prostate. Chemotherapy 49(6):269\u2013279","journal-title":"Chemotherapy"},{"key":"5048_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fsurg.2020.00007","volume":"7","author":"M Wenzel","year":"2020","unstructured":"Wenzel M, Theissen L, Preisser F, Lauer B, Wittler C, Humke C et al (2020) Complication rates after TRUS guided transrectal systematic and MRI-targeted prostate biopsies in a high-risk region for antibiotic resistances. Front Surg 7:7","journal-title":"Front Surg"},{"key":"5048_CR8","volume-title":"Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics","author":"EMA","year":"2019","unstructured":"EMA (2019) Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. EMA"},{"key":"5048_CR9","doi-asserted-by":"crossref","unstructured":"Umbehr M, Eich G, Mntener M (2020) Fluorochinolone unter Beschuss: Bedeutung f\u00fcr die Prophylaxe bei Prostatabiopsie?","DOI":"10.4414\/smf.2020.08461"},{"issue":"5","key":"5048_CR10","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1093\/jac\/dkz015","volume":"74","author":"I Karaiskos","year":"2019","unstructured":"Karaiskos I, Galani L, Sakka V, Gkoufa A, Sopilidis O, Chalikopoulos D et al (2019) Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother 74(5):1430\u20131437","journal-title":"J Antimicrob Chemother"},{"key":"5048_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ijid.2020.10.065","volume":"102","author":"T Delory","year":"2021","unstructured":"Delory T, Goujon A, Masson-Lecomte A, Arias P, Laurancon-Fretar A, Bercot B et al (2021) Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): a prospective cohort study. Int J Infect Dis 102:269\u2013274","journal-title":"Int J Infect Dis"},{"issue":"2","key":"5048_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00345-016-1867-6","volume":"35","author":"T Cai","year":"2017","unstructured":"Cai T, Gallelli L, Cocci A, Tiscione D, Verze P, Lanciotti M et al (2017) Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative. World J Urol 35(2):221\u2013228","journal-title":"World J Urol"},{"issue":"4","key":"5048_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000502851","volume":"103","author":"C D\u2019Elia","year":"2019","unstructured":"D\u2019Elia C, Mian C, Hanspeter E, Ladurner C, Palermo SM, Pycha S et al (2019) Efficacy and safety of two fosfomycin regimens as antimicrobial prophylaxis for transrectal prostate biopsy: a randomised study. Urol Int 103(4):433\u2013438","journal-title":"Urol Int"},{"issue":"2","key":"5048_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/2090598X.2019.1592636","volume":"17","author":"DMO Freitas","year":"2019","unstructured":"Freitas DMO, Moreira DM (2019) Fosfomycin trometamol vs ciprofloxacin for antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy: a meta-analysis of clinical studies. Arab J Urol 17(2):114\u2013119","journal-title":"Arab J Urol"},{"issue":"5","key":"5048_CR15","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.euf.2021.11.007","volume":"8","author":"TE Bjerklund Johansen","year":"2022","unstructured":"Bjerklund Johansen TE, Kulchavenya E, Lentz GM, Livermore DM, Nickel JC, Zhanel G et al (2022) Fosfomycin trometamol for the prevention of infectious complications after prostate biopsy: a consensus statement by an international multidisciplinary group. Eur Urol Focus 8(5):1483\u20131492","journal-title":"Eur Urol Focus"},{"key":"5048_CR16","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6"},{"issue":"2","key":"5048_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.juro.2017.01.103","volume":"198","author":"MA Liss","year":"2017","unstructured":"Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V et al (2017) An update of the American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol 198(2):329\u2013334","journal-title":"J Urol"},{"key":"5048_CR18","unstructured":"EAU Guidelines (2022) Edn. Presented at the EAU Annual Congress Amsterdam 2022"},{"issue":"6","key":"5048_CR19","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1590\/s1677-5538.ibju.2016.0619","volume":"43","author":"E Kisa","year":"2017","unstructured":"Kisa E, Altug MU, Gurbuz OA, Ozdemir H (2017) Fosfomycin: a good alternative drug for prostate biopsy prophylaxis the results of a prospective, randomized trial with respect to risk factors. Int Braz J Urol 43(6):1068\u20131074","journal-title":"Int Braz J Urol"},{"issue":"4","key":"5048_CR20","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1093\/cid\/cit704","volume":"58","author":"BJ Gardiner","year":"2014","unstructured":"Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT et al (2014) Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis 58(4):e101\u2013e105","journal-title":"Clin Infect Dis"},{"issue":"7","key":"5048_CR21","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/jac\/dkv067","volume":"70","author":"NJ Rhodes","year":"2015","unstructured":"Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N et al (2015) Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J Antimicrob Chemother 70(7):2068\u20132073","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"5048_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000355103","volume":"92","author":"FM Wagenlehner","year":"2014","unstructured":"Wagenlehner FM, Thomas PM, Naber KG (2014) Fosfomycin trometamol (3000 mg) in perioperative antibiotic prophylaxis of healthcare-associated infections after endourological interventions: a narrative review. Urol Int 92(2):125\u2013130","journal-title":"Urol Int"},{"issue":"2","key":"5048_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/JU.0000000000000814","volume":"204","author":"A Pilatz","year":"2020","unstructured":"Pilatz A, Dimitropoulos K, Veeratterapillay R, Yuan Y, Omar MI, MacLennan S et al (2020) Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. J Urol 204(2):224\u2013230","journal-title":"J Urol"},{"issue":"2","key":"5048_CR24","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/2019.5.FOCUS19272","volume":"47","author":"SL Rubeli","year":"2019","unstructured":"Rubeli SL, D\u2019Alonzo D, Mueller B, Bartlom\u00e9 N, Fankhauser H, Bucheli E et al (2019) Implementation of an infection prevention bundle is associated with reduced surgical site infections in cranial neurosurgery. Neurosurg Focus 47(2):E3","journal-title":"Neurosurg Focus"},{"issue":"6","key":"5048_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1473-3099(17)30176-7","volume":"17","author":"WP Weber","year":"2017","unstructured":"Weber WP, Mujagic E, Zwahlen M, Bundi M, Hoffmann H, Soysal SD et al (2017) Timing of surgical antimicrobial prophylaxis: a phase 3 randomised controlled trial. Lancet Infect Dis 17(6):605\u2013614","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"5048_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41391-018-0041-1","volume":"21","author":"CM Porter","year":"2018","unstructured":"Porter CM, Shrestha E, Peiffer LB, Sfanos KS (2018) The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis 21(3):345\u2013354","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05048-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:32:20Z","timestamp":1735853540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05048-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5048"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05048-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethical committee of northwestern and central Switzerland (EKNZ reference number: 2020-01849).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to partecipate"}}],"article-number":"356"}}